CONMED (CNMD) Fundamentals 2026 — P/E 23.5x, Revenue Analysis | SniperIQ
CONMED (CNMD) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CONMED's market cap?
CONMED (CNMD) has a market capitalization of approximately
What is CONMED's P/E ratio?
CONMED's trailing twelve-month P/E ratio is 23.5x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is CONMED?
CONMED runs a net profit margin of 4.0%, a gross margin of 53.6%, and an operating margin of 11.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CONMED generate?
CONMED reported revenue of
Does CONMED pay a dividend?
CONMED offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is CONMED financially healthy?
CONMED carries a debt-to-equity ratio of 0.85x and a current ratio of 2.29x, with a market beta of 0.93. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CONMED a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CONMED (CNMD) the key facts are: market cap
Track CONMED's full fundamentals live
Get CONMED's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.